GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (NAS:ESPR) » Definitions » Cyclically Adjusted PS Ratio

Esperion Therapeutics (Esperion Therapeutics) Cyclically Adjusted PS Ratio : 0.45 (As of Apr. 27, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Esperion Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Esperion Therapeutics's current share price is $1.90. Esperion Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $4.24. Esperion Therapeutics's Cyclically Adjusted PS Ratio for today is 0.45.

The historical rank and industry rank for Esperion Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

ESPR' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.18   Med: 1.71   Max: 13.38
Current: 0.47

During the past years, Esperion Therapeutics's highest Cyclically Adjusted PS Ratio was 13.38. The lowest was 0.18. And the median was 1.71.

ESPR's Cyclically Adjusted PS Ratio is ranked better than
86.55% of 736 companies
in the Drug Manufacturers industry
Industry Median: 2.06 vs ESPR: 0.47

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Esperion Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.287. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.24 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Esperion Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Esperion Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Cyclically Adjusted PS Ratio Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.30 3.90 0.87 1.28 0.70

Esperion Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.28 0.34 0.30 0.22 0.70

Competitive Comparison of Esperion Therapeutics's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's Cyclically Adjusted PS Ratio falls into.



Esperion Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Esperion Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.90/4.24
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Esperion Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Esperion Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.287/129.4194*129.4194
=0.287

Current CPI (Dec. 2023) = 129.4194.

Esperion Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 5.111 107.251 6.167
201906 0.036 108.070 0.043
201909 0.036 108.329 0.043
201912 0.036 108.420 0.043
202003 0.067 108.902 0.080
202006 7.356 108.767 8.753
202009 0.138 109.815 0.163
202012 0.359 109.897 0.423
202103 0.307 111.754 0.356
202106 1.550 114.631 1.750
202109 0.545 115.734 0.609
202112 0.417 117.630 0.459
202203 0.309 121.301 0.330
202206 0.298 125.017 0.308
202209 0.280 125.227 0.289
202212 0.256 125.222 0.265
202303 0.310 127.348 0.315
202306 0.236 128.729 0.237
202309 0.304 129.860 0.303
202312 0.287 129.419 0.287

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Esperion Therapeutics  (NAS:ESPR) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Esperion Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics (Esperion Therapeutics) Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Executives
Eric Warren officer: Chief Commercial Officer 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
J Martin Carroll director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Stephen Rocamboli director C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Sheldon L. Koenig officer: Chief Operating Officer C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joanne M. Foody officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Benjamin Looker officer: General Counsel C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Benjamin Halladay officer: Chief Financial Officer ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Biotech Target N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Alan Fuhrman director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Timothy M Mayleben director, officer: Pres & Chief Executive Officer 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Ashley Hall officer: Chief Development Officer C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108
Tracy M Woody director 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241
Richard Bartram officer: Chief Financial Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Nicole Vitullo director, 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121